Natixis Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.7M Buy
461,098
+215,350
+88% +$18M 0.05% 337
2026
Q1
$19.7M Sell
245,748
-7,334
-3% -$605K 0.03% 498
2025
Q4
$21.6M Sell
253,082
-4,220
-2% -$346K 0.03% 465
2025
Q3
$20M Buy
257,302
+20,574
+9% +$1.61M 0.03% 479
2025
Q2
$18.5M Buy
236,728
+56,684
+31% +$4.23M 0.03% 500
2025
Q1
$13.1M Sell
180,044
-108,399
-38% -$7.76M 0.02% 572
2024
Q4
$21.4M Buy
288,443
+98,554
+52% +$6.9M 0.04% 418
2024
Q3
$12.5M Sell
189,889
-58,516
-24% -$4.25M 0.02% 589
2024
Q2
$22.9M Buy
248,405
+26,038
+12% +$2.31M 0.05% 343
2024
Q1
$21.2M Sell
222,367
-5,470
-2% -$459K 0.05% 375
2023
Q4
$17.4M Buy
227,837
+49,311
+28% +$3.43M 0.05% 398
2023
Q3
$12.4M Sell
178,526
-110,428
-38% -$8.87M 0.04% 448
2023
Q2
$27.3M Buy
288,954
+21,842
+8% +$1.9M 0.08% 248
2023
Q1
$22.1M Buy
267,112
+16,890
+7% +$1.33M 0.08% 275
2022
Q4
$18.7M Buy
250,222
+55,254
+28% +$4.26M 0.07% 312
2022
Q3
$16.1M Buy
194,968
+14,943
+8% +$1.44M 0.07% 320
2022
Q2
$17.1M Buy
180,025
+4,468
+3% +$463K 0.08% 307
2022
Q1
$20.7M Buy
175,557
+20,841
+13% +$2.34M 0.08% 276
2021
Q4
$20M Buy
154,716
+7,914
+5% +$923K 0.08% 286
2021
Q3
$16.6M Sell
146,802
-6,634
-4% -$757K 0.07% 299
2021
Q2
$15.9M Buy
153,436
+17,484
+13% +$1.65M 0.07% 296
2021
Q1
$11.4M Sell
135,952
-7,301
-5% -$617K 0.06% 353
2020
Q4
$13.1M Buy
143,253
+17,462
+14% +$1.45M 0.08% 292
2020
Q3
$10M Buy
125,791
+6,927
+6% +$540K 0.06% 320
2020
Q2
$8.21M Buy
118,864
+11,554
+11% +$821K 0.05% 360
2020
Q1
$6.75M Sell
107,310
-50,274
-32% -$3.63M 0.06% 363
2019
Q4
$12.3M Buy
157,584
+4,167
+3% +$325K 0.09% 269
2019
Q3
$11.2M Buy
153,417
+2,898
+2% +$204K 0.09% 253
2019
Q2
$9.27M Sell
150,519
-1,722
-1% -$104K 0.08% 286
2019
Q1
$9.71M Sell
152,241
-14,076
-8% -$803K 0.09% 265
2018
Q4
$8.49M Sell
166,317
-5,700
-3% -$288K 0.08% 260
2018
Q3
$9.98M Sell
172,017
-67,656
-28% -$3.31M 0.09% 259
2018
Q2
$11.6M Sell
239,673
-230,835
-49% -$10.8M 0.11% 213
2018
Q1
$21.9M Buy
470,508
+2,529
+0.5% +$110K 0.22% 95
2017
Q4
$17.6M Buy
467,979
+94,062
+25% +$3.45M 0.18% 124
2017
Q3
$13.6M Buy
373,917
+124,086
+50% +$4.73M 0.14% 160
2017
Q2
$9.85M Buy
249,831
+627
+0.3% +$22.9K 0.11% 223
2017
Q1
$7.81M Buy
249,204
+183,228
+278% +$5.74M 0.09% 269
2016
Q4
$2.06M Sell
65,976
-4,902
-7% -$159K 0.02% 667
2016
Q3
$2.85M Buy
70,878
+93
+0.1% +$3.5K 0.04% 561
2016
Q2
$2.35M Buy
70,785
+4,137
+6% +$142K 0.03% 583
2016
Q1
$1.96M Buy
66,648
+8,796
+15% +$243K 0.03% 625
2015
Q4
$1.52M Sell
57,852
-13,158
-19% -$342K 0.03% 668
2015
Q3
$1.68M Sell
71,010
-5,478
-7% -$132K 0.03% 644
2015
Q2
$1.82M Sell
76,488
-3,792
-5% -$85.6K 0.03% 659
2015
Q1
$1.91M Buy
+80,280
New +$1.8M 0.03% 633
2014
Q3
Sell
-18,078
Closed -$259K 1072
2014
Q2
$259K Buy
18,078
+1,488
+9% +$20.2K ﹤0.01% 1198
2014
Q1
$205K Sell
16,590
-19,152
-54% -$221K ﹤0.01% 1197
2013
Q4
$392K Sell
35,742
-31,614
-47% -$356K 0.01% 948
2013
Q3
$782K Buy
67,356
+624
+0.9% +$7.3K 0.01% 738
2013
Q2
$747K Buy
+66,732
New +$790K 0.01% 730

Other funds holding EW

Natixis Advisors's EW Position: Q2 2026 in Review

Natixis Advisors increased its Edwards Lifesciences (EW) stake by 88% in Q2 2026, buying an estimated $18M and bringing the position to 461,098 shares worth $41.7M. The position accounts for 0.05% of the portfolio, ranked #337.

Natixis Advisors first reported a position in EW in Q2 2013 and has held it in 51 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Natixis Advisors held 461,098 shares of Edwards Lifesciences worth $41.7M as of Q2 2026.
  • Natixis Advisors bought 215,350 Edwards Lifesciences shares in Q2 2026, an estimated $18M.
  • Edwards Lifesciences made up 0.05% of Natixis Advisors's portfolio in Q2 2026, its #337 holding.
  • Natixis Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.